Literature DB >> 32089240

Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.

Jianqin Zhang1, Chuxuan Wu1, Li Gao1, Guanhua Du2, Xuemei Qin3.   

Abstract

Decoctions prepared from the roots of Astragali Radix are known as "Huangqi" and are widely used in traditional Chinese medicine for treatment of viral and bacterial infections, inflammation, as well as cancer. Astragaloside IV (AS-IV), one of the major compounds from the aqueous extract of Astragalus membranaceus, is a cycloartane-type triterpene glycoside chemical. To date, many studies in cellular and animal models have demonstrated that AS-IV possesses potent protective effects in cardiovascular, lung, kidney and brain. Based on studies over the past several decades, this review systematically summarizes the pharmacological effects, pharmacokinetics and the toxicity of AS-IV. We analyze in detail the pharmacological effects of AS-IV on neuroprotection, liver protection, anti-cancer and anti-diabetes, attributable to its antioxidant, anti-inflammatory, anti-apoptotic properties, and the roles in enhancement of immunity, attenuation of the migration and invasion of cancer cells and improvement of chemosensitivity of chemotherapy drugs. In addition, the latest developments in the combination of AS-IV and other active ingredients of traditional Chinese medicine or chemical drugs are detailed. These pharmacological effects are associated with multiple signaling pathways, including the Raf-MEK-ERK pathway, EGFR-Nrf2 signaling pathway, Akt/PDE3B signaling pathway, AMPK signaling pathway, NF-κB signaling pathway, Nrf2 antioxidant signaling pathways, PI3K/Akt/mTOR signaling pathway, PKC-α-ERK1/2-NF-κB pathway, IL-11/STAT3 signaling pathway, Akt/GSK-3β/β-catenin pathway, JNK/c-Jun/AP-1 signaling pathway, PI3K/Akt/NF-κB pathway, miRNA-34a/LDHA pathway, Nox4/Smad2 pathway, JNK pathway and NF-kB/PPARγ pathway. This review will provide an overall understanding of the pharmacological functions of astragaloside IV on neuroprotection, liver protection, anti-cancer and anti-diabetes. In light of this, AS-IV will be a potent alternative therapeutic agent for treatment of the above mentioned diseases.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-apoptosis; Anticancer; Antioxidation; Astragaloside IV; Combined medication; Glucose regulation; Immunomodulatory effect; Inhibition of inflammation; Pharmacokinetics; Toxicity

Mesh:

Substances:

Year:  2019        PMID: 32089240     DOI: 10.1016/bs.apha.2019.08.002

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  43 in total

1.  Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-κB/STAT3 signaling pathway.

Authors:  Liang Min; Haiqiao Wang; Hong Qi
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 2.  The Role of Saponins in the Treatment of Neuropathic Pain.

Authors:  Bei Tan; Xueqing Wu; Jie Yu; Zhong Chen
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

3.  Effectiveness of Chinese herbal medicine combined with Western medicine on deferring dialysis initiation for nondialysis chronic kidney disease stage 5 patients: a multicenter prospective nonrandomized controlled study.

Authors:  Yifan Wu; Chuang Li; Lei Zhang; Chuan Zou; Peng Xu; Zehuai Wen; Wenwei Ouyang; Nizhi Yang; Min Zhang; Qizhan Lin; Fuhua Lu; Lixin Wang; Kun Bao; Daixin Zhao; Lizhe Fu; Xinfeng Guo; Lihong Yang; Aihua Ou; Zehui He; Heng Weng; Jianmin Li; Wei Shi; Xiaoqin Wang; Liqun Song; Yongli Zhan; Wei Sun; Lianbo Wei; Niansong Wang; Dingkun Gui; Jihong Zhan; Ying Lu; Hongyu Chen; Yuning Liu; Hongtao Yang; Ming Chen; Yiping Wang; Peiqing Zhang; Yueyi Deng; Lanfen Meng; Xiaohong Cheng; Feng Li; Dajun Yu; Damin Xu; Jing'ai Fang; Hongyan Li; Junzhou Fu; Yuansheng Xie; Wenge Li; Jinghong Zhao; Yuanhang Huang; Zhaoyu Lu; Guobin Su; Xindong Qin; Yuan Xu; Yu Peng; Haijing Hou; Lili Deng; Hui Liu; Xina Jie; Lichang Liu; Fang Tang; Hongfei Pei; Ping Li; Wei Mao; Xusheng Liu
Journal:  Ann Transl Med       Date:  2021-03

4.  Exploring the Oxidative Stress Mechanism of Buyang Huanwu Decoction in Intervention of Vascular Dementia Based on Systems Biology Strategy.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Yaqiao Yi; Shanshan Wang; Jinwen Ge
Journal:  Oxid Med Cell Longev       Date:  2021-03-03       Impact factor: 6.543

5.  Astragaloside IV Protects 6-Hydroxydopamine-Induced SH-SY5Y Cell Model of Parkinson's Disease via Activating the JAK2/STAT3 Pathway.

Authors:  ZhengHu Xu; Dongfeng Yang; Xiaojing Huang; Huai Huang
Journal:  Front Neurosci       Date:  2021-03-23       Impact factor: 4.677

Review 6.  Neuroprotective Effect for Cerebral Ischemia by Natural Products: A Review.

Authors:  Qian Xie; Hongyan Li; Danni Lu; Jianmei Yuan; Rong Ma; Jinxiu Li; Mihong Ren; Yong Li; Hai Chen; Jian Wang; Daoyin Gong
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

7.  Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway.

Authors:  Yenan Mo; Xina Jie; Lixin Wang; Chunlan Ji; Yueyu Gu; Zhaoyu Lu; Xusheng Liu
Journal:  BMC Complement Med Ther       Date:  2021-08-10

Review 8.  Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism.

Authors:  Jia-Li Zhang; Wen-Xiong Li; Yue Li; Man-Sau Wong; Yong-Jun Wang; Yan Zhang
Journal:  Phytomedicine       Date:  2020-08-05       Impact factor: 5.340

9.  Astragalus mongholicus Bunge Water Extract Exhibits Anti-inflammatory Effects in Human Neutrophils and Alleviates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice.

Authors:  Wei-Jen Cheng; Chih-Chao Chiang; Cheng-Yu Lin; Yu-Li Chen; Yann-Lii Leu; Jia-Yu Sie; Wen-Ling Chen; Chung-Yuan Hsu; Jong-Jen Kuo; Tsong-Long Hwang
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

10.  Protective Effects of Astragaloside IV on Uric Acid-Induced Pancreatic β-Cell Injury through PI3K/AKT Pathway Activation.

Authors:  Zhenhuan Jiang; Gang Wang; Lingling Meng; Yunzhao Tang; Min Yang; Changlin Ni
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.